Alzheimer’s & Dementia: Translational Research & Clinical Interventions (Jan 2021)

A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

  • Qiliang He,
  • Kay M. Colon‐Motas,
  • Alyssa F. Pybus,
  • Lydia Piendel,
  • Jonna K. Seppa,
  • Margaret L. Walker,
  • Cecelia M. Manzanares,
  • Deqiang Qiu,
  • Svjetlana Miocinovic,
  • Levi B. Wood,
  • Allan I. Levey,
  • James J. Lah,
  • Annabelle C. Singer

DOI
https://doi.org/10.1002/trc2.12178
Journal volume & issue
Vol. 7, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction We and collaborators discovered that flickering lights and sound at gamma frequency (40 Hz) reduce Alzheimer's disease (AD) pathology and alter immune cells and signaling in mice. To determine the feasibility of this intervention in humans we tested the safety, tolerability, and daily adherence to extended audiovisual gamma flicker stimulation. Methods Ten patients with mild cognitive impairment due to underlying AD received 1‐hour daily gamma flicker using audiovisual stimulation for 4 or 8 weeks at home with a delayed start design. Results Gamma flicker was safe, tolerable, and adherable. Participants’ neural activity entrained to stimulation. Magnetic resonance imaging and cerebral spinal fluid proteomics show preliminary evidence that prolonged flicker affects neural networks and immune factors in the nervous system. Discussion These findings show that prolonged gamma sensory flicker is safe, tolerable, and feasible with preliminary indications of immune and network effects, supporting further study of gamma stimulation in AD.

Keywords